T1	Participants 0 91	Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer
T2	Participants 162 262	Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor,
T3	Participants 283 371	US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer
T4	Participants 428 496	ARIES (Avastin Regimens: Investigation of Effectiveness and Safety),
T5	Participants 645 813	2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology
T6	Participants 925 952	4 months before enrollment.
T7	Participants 1167 1202	1967 patients with first-line NSCLC
T8	Participants 1222 1254	median follow-up was 12.5 months
T9	Participants 1274 1367	Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers.
T10	Participants 1405 1415	6.6 months
T11	Participants 1484 1495	13.0 months
T12	Participants 1756 1929	ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC.
